In contrast, in a comparator cohort of MCL patients treated with frontline standard chemo‐immunotherapy regimens [17], TP53 VAF appeared to have the opposite effect, although this was not significant for PFS (HR 0.98; p = 0.2) or OS (HR 0.97; p = 0.06). Here, TP53 is linked to mantle cell lymphoma.